Bill

Bill > A4637


NJ A4637

NJ A4637
Provides that sterile syringe access programs are inherently beneficial uses.


summary

Introduced
10/22/2018
In Committee
10/22/2018
Crossed Over
Passed
Dead
01/08/2020

Introduced Session

2018-2019 Regular Session

Bill Summary

This bill would revise the definition of "inherently beneficial use in the "Municipal Land Use Law," P.L.1975, c.291 (C.40:55D-1 et seq.) (MLUL) to include a sterile syringe access program. Under the MLUL, if a use is deemed inherently beneficial it presumptively satisfies the positive criteria for the grant of a use variance under subsection d. of section 57 of P.L.1975, c.291 (C.40:55-70). Sterile syringe access programs are designed to prevent the spread of HIV, hepatitis C, and other blood borne pathogens, and have been proven effective in reducing the spread of these pathogens without adverse social impacts or an increase in drug abuse. Additionally, the programs provide drug users with a bridge to treatment and other social services. This bill would make it easier for the programs to be established, providing more individuals with access to the program benefits.

AI Summary

This bill would revise the definition of "inherently beneficial use" in the Municipal Land Use Law to include a sterile syringe access program. Sterile syringe access programs are designed to prevent the spread of HIV, hepatitis C, and other bloodborne pathogens, and have been proven effective in reducing the spread of these diseases without adverse social impacts or an increase in drug abuse. By including these programs in the definition of "inherently beneficial use," the bill would make it easier for the programs to be established, providing more individuals with access to the program benefits.

Committee Categories

Health and Social Services

Sponsors (1)

Last Action

Introduced, Referred to Assembly Human Services Committee (on 10/22/2018)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...